iVeena Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $345K

  • Investors
  • 8

iVeena General Information

Description

Developer of a novel proprietary drug candidate designed to treat ophthalmic diseases. The company's drug candidate offers a cure for post-surgery cataract inflammation, macular degeneration, diabetic retinopathy, and glaucoma and it uses novel approaches including delivery from the lens capsule, enabling doctors to treat corneal diseases and myopic conditions effectively.

Contact Information

Website
www.iveenamed.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 391 Chipeta Way
  • Suite I
  • Salt Lake City, UT 84108
  • United States
+1 (801) 000-0000
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 391 Chipeta Way
  • Suite I
  • Salt Lake City, UT 84108
  • United States
+1 (801) 000-0000

iVeena Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

iVeena Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Grant 26-Oct-2023 $345K 00.000 Completed Clinical Trials - Phase 2
10. Grant 31-Aug-2022 00.000 00.000 Completed Clinical Trials - Phase 2
9. Grant 31-Jul-2021 000 00.000 Completed Clinical Trials - Phase 2
8. Later Stage VC (Series B) 08-Jul-2020 00.000 00.000 000.00 Completed Clinical Trials - Phase 2
7. Grant 29-Sep-2018 00000 00.00 Completed Clinical Trials - Phase 2
6. Grant 30-Jun-2018 00000 00.00 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series A1) 04-Dec-2017 00.00 00.00 000.00 Completed Clinical Trials - Phase 2
4. Accelerator/Incubator 00.00 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series A) 12-Jul-2016 $1.3M $1.3M 00.00 Completed Clinical Trials - Phase 2
2. Grant 31-Dec-2015 $217K Completed Clinical Trials - Phase 2
To view iVeena’s complete valuation and funding history, request access »

iVeena Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series A-1 0,000,000 00.000000 00.00 00.00 00 00.00 00.00
Series A 2,190,000 $0.000100 $1 $1 1x $1 13.87%
To view iVeena’s complete cap table history, request access »

iVeena Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a novel proprietary drug candidate designed to treat ophthalmic diseases. The company's drug candidate offe
Drug Discovery
Salt Lake City, UT
6 As of 2024
00.000
0000000000 00.000

000000

nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qu
000000000000000
Palo Alto, CA
000 As of 0000
00000
00000 0000-00-00
00000000 00000

000000

nim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip e
0000000000000
Richmond, CA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

iVeena Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kodiak Sciences Formerly VC-backed Palo Alto, CA 000 00000 00000000 00000
Sangamo Therapeutics Formerly VC-backed Richmond, CA 000 00000 00000000 00000
Pfizer Pakistan Corporation Karachi, Pakistan
Merck & Co. Corporation Rahway, NJ 00000 0000 000000000 - 0000
To view iVeena’s complete competitors history, request access »

iVeena Patents

  • 5

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 2

    Granted

  • 3

    Pending

  • 000

    Expiring in next 12 mo

iVeena Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3205654-A1 Treatment of astigmatism Pending 01-Feb-2021 000000000
AU-2022212028-A1 Treatment of astigmatism Active 01-Feb-2021 0000000000
EP-4284392-A1 Treatment of astigmatism Pending 01-Feb-2021 0000000000
AU-2022212028-B2 Treatment of astigmatism Active 01-Feb-2021 0000000000
US-20240091255-A1 Treatment of astigmatism Pending 01-Feb-2021 A61K33/34
To view iVeena’s complete patent history, request access »

iVeena Executive Team (9)

Name Title Board Seat
Gerald Simmons Chief Executive Officer and Board Member
Ned Weinshenker Ph.D Chief Operating Officer & Board Member
Balamurali Ambati Ph.D Founder, Board Member & President
Michael Burr Vice President, Product Development
Sarah Molokhia Ph.D Vice President, Research & Development
You’re viewing 5 of 9 executive team members. Get the full list »

iVeena Board Members (10)

Name Representing Role Since
Amir Shojaei Ph.D Self Board Member 000 0000
Balamurali Ambati Ph.D iVeena Founder, Board Member & President 000 0000
Barry Hanover Self Board Member 000 0000
Gerald Simmons iVeena Chief Executive Officer and Board Member 000 0000
Jayakrishna Ambati MD Self Vice President of Advanced Ocular Design & Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

iVeena Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

iVeena Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Eye Institute Government 000 0000 000000 0
Mountain Pacific Partners Venture Capital Minority 000 0000 000000 0
National Science Foundation Government 000 0000 000000 0
Park City Angels Angel Group Minority 000 0000 000000 0
SLC Angels Angel Group Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial

iVeena FAQs

  • When was iVeena founded?

    iVeena was founded in 2006.

  • Who is the founder of iVeena?

    Balamurali Ambati Ph.D is the founder of iVeena.

  • Who is the CEO of iVeena?

    Gerald Simmons is the CEO of iVeena.

  • Where is iVeena headquartered?

    iVeena is headquartered in Salt Lake City, UT.

  • What is the size of iVeena?

    iVeena has 6 total employees.

  • What industry is iVeena in?

    iVeena’s primary industry is Drug Discovery.

  • Is iVeena a private or public company?

    iVeena is a Private company.

  • What is iVeena’s current revenue?

    The current revenue for iVeena is 00000.

  • How much funding has iVeena raised over time?

    iVeena has raised $5.93M.

  • Who are iVeena’s investors?

    National Eye Institute, Mountain Pacific Partners, National Science Foundation, Park City Angels, and SLC Angels are 5 of 8 investors who have invested in iVeena.

  • Who are iVeena’s competitors?

    Kodiak Sciences, Sangamo Therapeutics, Pfizer Pakistan, and Merck & Co. are competitors of iVeena.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »